Persistent Pulmonary Hypertension (PPHN) : F. Hazel R. Villa, MD PL1

Persistent Pulmonary
Hypertension (PPHN)
F. Hazel R. Villa, MD
PL1
Objectives
 to review the fetal,transitional and postnatal
circulation in relation to PPHN
 To understand the pathophysiology of PPHN

as it applies to clinical manifestations and
management
Pulmonary vessels
VASOCONSTRICTORS VASODILATORS
(Maintain high fetal PVR) (Decrease PVR during
transition)
Norepinephrine
A-adrenergic stimulation PGI2, PGD2, PGE2
Hypoxia Nitric oxide
Endothelin Cyclic GMP
Thromboxanes Cyclic AMP
Leukotrienes Oxygen
Platelet activating factor Adenosine
PGF2a Bradykinin
Fetal circulation
Fetal circulation
 pO2, PGI2, NO
 ADMA -- competes with arginine
inhibit NOS
 Vasoconstriction
Postnatal circulation
Transitional circulation
Transitional to postnatal
 At birth
 increase in NO, NOS- cGMP
increase guanylate cyclase- cGMP
increase in PGI2 (effect of estrogen) cAMP
DDAH metabolizes ADMA
 Vasodilatation
 At birth
ventilation
increase pulmonary blood flow
Oxygenation
 Oxygen- stimulates NOS, COX1
 Pulmonary blood flow- release of NO, PGI2
 Evidence: NO-cGMP pathway is a more potent

modulator of pulmonary vascular tone
Increase in SVR
 Removal of the placenta
 Catecholamine associated with birth
 Cold environment
Postnatal decrease in PVR
 Expansion of the lung
 Adequate ventilation, oxygenation
 Clearance of fetal lung fluid

3 types of abnormalities
 Maladaptation
 Maldevelopment
 Underdevelopment
Maladaptation
 Prototype: Meconium aspiration pneumonia
 Pneumonia, RDS
 Obstruction of the airways

 Chemical pneumonitis
 Release of endothelin,thromboxane
vasoconstrictors
Maldevelopment
 Prototype: Idiopathic PPHN
 (“black lung” PPHN)
 Vessel wall thickening
 Smooth muscle hyperplasia
 Cause – intrauterine exposure to NSAID
 constriction of ductus arteriosus
 genetic
Maldevelopment
 Disruption of NO-cGMP pathway
 Disruption of PGI2-cAMP pathway
 Guanylate cyclase is less active
 Increased ROS (reactive oxygen species)
vasoconstrictor
 Increased thromboxane, endothelin
Underdevelopment
 Prototype: Congenital diaphragmatic hernia
 Pulmonary hypoplasia
 Decreased cross sectional area of pulmonary
vasculature
 Decreased pulmonary blood flow
 Abnormal muscular hypertrophy of the pulm
arterioles
Clinical signs and symptoms
 PE:
 meconium staining
 Prominent precordial impulse
 Narrow split accentuated P2
 Systolic murmur LLSB
Labs
 CXR: CDH, decreased vascular markings,
parenchymal disease
 ECG: RV predominance, ST elevation
 ABG: hyperoxic test (pO2 < 100 at 100% O2)
 Pre and postductal ABG (R radial artery:
umbilical artery/lower extremity)
 10-15% saturation and or 10-15mmHg pO2
Labs
 Echocardiography
 Structural heart disease is determined
 R-L shunting (Ductus or FO)
 Pulmonary arterial pressure is measured
Management
 Oxygen 100% pO2 should be kept between
50-90mmHg (O2 saturation >90%)
 Correct factors promoting vasoconstriction:
hypoglycemia, hypocalcemia, anemia, hypovolemia
 Optimize cardiac function (inotropic agents, volume

expansion
 Mechanical ventilation
 Surfactant
Management
 Inhaled Nitric oxide- an ideal selective
pulmonary vasodilator
 OI of >25
 OI=(MAP x FiO2)/pO2 x 100
 Contraindications: CHD which are PDA dependent
 (aortic stenosis, interrupted aortic arch, hypolastic heart
syndrome)
 May worsen pulmonary edema in obstructed TAPVR
Used to transport patient for ECMO

Management
 ECMO
 Goal of this treatment:
 maintain adequate tissue oxygenation and
 avoid irreversible lung injury, while PVR
decreases and correcting pulm HTN
 ECMO if OI is >40
Other Pulmonary Vasodilators
 Sildenafil- PDE5 inhibitor increased cGMP
 Milrinone- PDE3 inhibitor increased cAMP
 Inhaled PGI2
 Superoxide dismutase-superoxide scavenger
 Dilates pulm vessels, and increase endogenous NO
References
 http://neoreviews.aappublications.org/cgi/content/full/8/1/e14
 http://www.utdol.com/utd/content/topic.do?topicKey=neonatol
/1427&view=print
 www.emedicine.com/ped/topic2530.htm
 www.emedicine.com/PED/topic2530.htm
 phassociation.org/medical/.../Summer_2006/persisten
t_ph_newborn.pdf
Thank you!

Persistent Pulmonary Hypertension (PPHN) : F. Hazel R. Villa, MD PL1

Uploaded by

Copyright:

Available Formats

Persistent Pulmonary Hypertension (PPHN) : F. Hazel R. Villa, MD PL1

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Persistent Pulmonary Hypertension (PPHN) : F. Hazel R. Villa, MD PL1

Uploaded by

Copyright:

Available Formats

Persistent Pulmonary

 To understand the pathophysiology of PPHN

 Evidence: NO-cGMP pathway is a more potent

 Catecholamine associated with birth

 Adequate ventilation, oxygenation

 Clearance of fetal lung fluid

 Obstruction of the airways

 Optimize cardiac function (inotropic agents, volume

Used to transport patient for ECMO

You might also like

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.